Compare AbCellera Biologics Inc (ABCL) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Berkshire Hathaway Inc Class B — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Berkshire Hathaway Inc Class B trades at $496. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| ABCL | BRK.B | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Financials |
52-Week High | $8.12 | $513.70 |
52-Week Low | $2.78 | $459.10 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BRK.B trades at $495.03, down 2.3% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The stock lacks key valuation ratios like P/E and P/B in the provided data, indicating potential data gaps. Analyst consensus is positive with 57% buy ratings and no sell recommendations.
The outlook remains cautiously optimistic given strong analyst support and bullish technical trends, though overbought RSI levels near 80 suggest short-term consolidation risks. Key risks include market volatility and reliance on broad economic health, but institutional confidence provides a stable foundation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
